Advertisement
The American Journal of Cardiology®
Advanced SearchSave search
Roundtable discussion| Volume 107, ISSUE 9, P1357-1364, May 01, 2011

The Editor's Roundtable: Pathophysiology and Management of Hyponatremia and the Role of Vasopressin Antagonists

  • Vincent E. Friedewald
    Correspondence
    Corresponding author: Tel: 512-264-1611; fax: 512-264-7034
    Affiliations
    Associate Editor, The American Journal of Cardiology, Adjunct Senior Research Professor, Indiana University School of Medicine, Indianapolis, Indiana, and Research Professor, College of Science, University of Notre Dame, Notre Dame, Indiana
    Search for articles by this author
  • Michael Emmett
    Affiliations
    Chairman of Internal Medicine, Baylor University Medical Center, Dallas, Texas
    Search for articles by this author
  • Mihai Gheorghiade
    Affiliations
    Professor of Medicine and Surgery and Director of Experimental Therapeutics, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois
    Search for articles by this author
  • William C. Roberts
    Affiliations
    Editor-in-Chief, The American Journal of Cardiology and Baylor University Medical Center Proceedings, Executive Director, Baylor Heart and Vascular Institute of Baylor University Medical Center, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, Texas
    Search for articles by this author
DOI:https://doi.org/10.1016/j.amjcard.2010.10.033
The Editor's Roundtable: Pathophysiology and Management of Hyponatremia and the Role of Vasopressin Antagonists
Previous ArticleUsefulness of Total Lymphocyte Count as Predictor of Outcome in Patients With Chronic Heart Failure
Next ArticleReal-Time Three-Dimensional Transesophageal Echocardiography for Assessment of Mitral Valve Functional Anatomy in Patients With Prolapse-Related Regurgitation
      This article is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. , Rockville, Maryland.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Rozen-Zvi
        • Yahav D.
        • Gheorghiade M.
        • Korzets A.
        • Leibovici L.
        • Gafter U.
        Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.
        Am J Kidney Dis. 2010; 56: 325-337
        View in Article
        • Schrier R.W.
        • Gross P.
        • Gheorghiade M.
        • Berl T.
        • Verbalis J.G.
        • Czerwiec F.S.
        • Orlandi C.
        • SALT Investigators
        Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
        N Engl J Med. 2006; 355: 2099-2112
        View in Article
        • Dunlay S.M.
        • Gheorghiade M.
        • Reid K.J.
        • Allen L.A.
        • Chan P.S.
        • Hauptman P.J.
        • Zannad F.
        • Maggioni A.P.
        • Swedberg K.
        • Konstam M.A.
        • Spertus J.A.
        Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial.
        Eur J Heart Fail. 2010; 12: 367-374
        View in Article
        • Gheorghiade M.
        • Abraham W.T.
        • Albert N.M.
        • Gattis Stough W.
        • Greenberg B.H.
        • O'Connor C.M.
        • She L.
        • Yancy C.W.
        • Young J.
        • Fonarow G.C.
        • OPTIMIZE-HF Investigators and Coordinators
        Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.
        Eur Heart J. 2007; 28: 980-988
        View in Article
        • Gheorghiade M.
        • Rossi J.S.
        • Cotts W.
        • Shin D.D.
        • Hellkamp A.S.
        • Piña I.L.
        • Fonarow G.C.
        • DeMarco T.
        • Pauly D.F.
        • Rogers J.
        • DiSalvo T.G.
        • Butler J.
        • Hare J.M.
        • Francis G.S.
        • Stough W.G.
        • O'Connor C.M.
        Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial.
        Arch Intern Med. 2007; 167: 1998-2005
        View in Article
        • Rossi J.
        • Bayram M.
        • Udelson J.E.
        • Lloyd-Jones D.
        • Adams K.F.
        • Oconnor C.M.
        • Stough W.G.
        • Ouyang J.
        • Shin D.D.
        • Orlandi C.
        • Gheorghiade M.
        Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
        Acute Card Care. 2007; 9: 82-86
        View in Article
        • Schrier R.W.
        • Gross P.
        • Gheorghiade M.
        • Berl T.
        • Verbalis J.G.
        • Czerwiec F.S.
        • Orlandi C.
        • SALT Investigators
        Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
        N Engl J Med. 2006; 355: 2099-2112
        View in Article

      Article Info

      Footnotes

      This discussion took place on July 15, 2010.

      Identification

      DOI: https://doi.org/10.1016/j.amjcard.2010.10.033

      Copyright

      © 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      • The Difficult Combination of Low Serum Sodium and Heart Failure
        American Journal of CardiologyVol. 108Issue 5
        • Preview
          I read every word of the recent Editor's Roundtable on hyponatremia and the role of vasopressin antagonists,1 a fascinating review of physiology as well as pathophysiology. Franny Moore (a remarkable surgeon!) was the first to show, in the early 1950s, that many chronic diseases, including heart failure, demonstrated the paradox of low serum sodium but an increase in total body sodium and water.
        • Full-Text
        • PDF
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX